Delivery of therapeutic proteins to the mucosa using genetically modified microflora

Author: Steidler, Lothar

Source: Expert Opinion on Drug Delivery, Volume 2, Number 4, 1 July 2005 , pp. 737-746(10)

Publisher: Informa Healthcare

Buy & download fulltext article:


Price: $99.00 plus tax (Refund Policy)


Drug delivery through mucosal surfaces offers a panorama of opportunities. The advantages are clear and include safety, ease of administration and higher social acceptance, although the major disadvantages are drug availability and appropriate drug targeting. Most mucosa are well equipped to manage the presence of bacteria and many are actually permanently colonised with a specific microflora. Such microbiota may become attractive tools for the delivery of a specific niche of protein therapeutics. These proteins can be produced from genetically modified microbes that are common to the mucosa, and their delivery to the host tissues has been demonstrated. This concept is being developed for the delivery of proteins to the intestine, but has also been applied in delivery to the vagina, nose and mouth.

Keywords: antibiotics; cytokines; genetically modified microflora; mucosa; therapeutic proteins

Document Type: Review Article


Publication date: July 1, 2005

More about this publication?
Related content


Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page